High Expression of RhoBTB3 Predicts Favorable Chemothrapy Outcomes in non-M3 Acute Myeloid Leukemia

Area of Science:

• Hematology
• Molecular Biology
• Oncology

Background:

• Rho family GTPases' roles in acute myeloid leukemia (AML) remain underexplored.
• Systematic analysis of Rho GTPases in AML prognosis is needed.

Purpose of the Study:

• To investigate the expression patterns and prognostic significance of Rho family GTPases in AML.
• To identify potential biomarkers for treatment selection in non-M3 AML.

Main Methods:

• Expression analysis of 21 Rho GTPases in AML using GEPIA database.
• Validation of RhoBTB3 differential expression via RT-qPCR.
• Kaplan-Meier and Multivariate Cox analyses for prognostic value assessment.
• Gene functional enrichment analysis (GO, KEGG, PPI).

Main Results:

• High RhoBTB3 expression correlated with longer overall survival (OS) and event-free survival (EFS) in chemotherapy-treated non-M3 AML patients.
• RhoBTB3 did not show prognostic significance in allo-HSCT group; allo-HSCT mitigated poor prognosis associated with low RhoBTB3.
• Functional enrichment linked RhoBTB3 to extracellular matrix and cytokine-cytokine receptor interactions.

Conclusions:

• RhoBTB3 serves as a prognostic marker for non-M3 AML.
• RhoBTB3 expression may assist in choosing between chemotherapy and allo-HSCT.
• Further research is required to elucidate RhoBTB3's role in AML pathogenesis.